- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT06847542
En undersøgelse af 36-ugers påfyldningsudveksling af portleveringssystem (PDS) med ranibizumab i NAMD (Sightspire)
En fase IIIb, multicenter, enkeltarmsundersøgelse, der vurderer effektiviteten, sikkerhed og patient rapporterede resultater af et 36-ugers påfyldningsudvekslingsregime for portleveringssystemet med ranibizumab hos patienter med neovaskulær aldersrelateret makuladegeneration
The purpose of this study is to evaluate the effectiveness, safety, and PROs of the port delivery system with ranibizumab 100 milligrams/milliliters (mg/mL) refilled every 36 weeks (Q36W) in participants with nAMD.
Studieoversigt
Status
Betingelser
Intervention / Behandling
Undersøgelsestype
Tilmelding (Anslået)
Fase
- Fase 3
Kontakter og lokationer
Studiekontakt
- Navn: Fastest response: use the inquiry form. https://www.gene.com/contact-us/submit-medical-inquiry
Undersøgelse Kontakt Backup
- Navn: Reference Study ID Number: MR45625 https://forpatients.roche.com/ No attachments to email below.
- Telefonnummer: 888-662-6728 (U.S.)
- E-mail: global-roche-genentech-trials@gene.com
Studiesteder
-
-
-
Aarhus N, Danmark, 8200
- Rekruttering
- Aarhus Universitetshospital
-
Glostrup Municipality, Danmark, 2600
- Rekruttering
- Rigshospitalet Glostrup
-
-
-
-
-
Bristol, Det Forenede Kongerige, BS1 2LX
- Rekruttering
- Bristol Eye Hospital
-
Gloucester, Det Forenede Kongerige, GL1 3NN
- Rekruttering
- Gloucestershire Royal Hospital
-
London, Det Forenede Kongerige, EC1V 2PD
- Rekruttering
- Moorfields Eye Hospital NHS Foundation Trust
-
-
Leicestershire
-
Leicester, Leicestershire, Det Forenede Kongerige, LE1 5WW
- Rekruttering
- Leicester Royal Infirmary
-
-
-
-
-
Lyon, Frankrig, 69003
- Rekruttering
- Hopital Edouard Herriot - CHU Lyon
-
Montauban, Frankrig, 82000
- Rekruttering
- Clinique Honore Cave
-
Paris, Frankrig, 75012
- Rekruttering
- CHNO des Quinze Vingts
-
Poitiers, Frankrig, 86021
- Rekruttering
- CHU Poitiers - CHR La Miletrie
-
Strasbourg, Frankrig, 67091
- Rekruttering
- CHU Strasbourg - Nouvel Hopital Civil
-
-
Paris
-
Nantes, Paris, Frankrig, 44300
- Rekruttering
- Institut Ophtalmologique De l Ouest Jules Verne
-
-
-
-
-
Chaïdári, Grækenland, 124 62
- Rekruttering
- Attikon University General Hospital
-
Heraklon, Grækenland, 711 10
- Rekruttering
- University General Hospital of Heraklion
-
Larissa, Grækenland, 412 21
- Rekruttering
- University Hospital of Larissa
-
-
Attica
-
Athens, Attica, Grækenland, 115 27
- Rekruttering
- "G.Gennimatas" General Hospital of Athens
-
-
-
-
Campania
-
Naples, Campania, Italien, 80131
- Rekruttering
- Ospedale Monaldi - AORN dei Colli
-
-
Emilia-Romagna
-
Cona (Ferrara), Emilia-Romagna, Italien, 44122
- Rekruttering
- Azienda Ospedaliero - Universitaria di Ferrara - Arcispedale Sant'Anna, Sede Ospedale di Cona;UO di Clinica Oculistica
-
-
Lazio
-
Rome, Lazio, Italien, 00186
- Rekruttering
- Ospedale Isola Tiberina - Gemelli Isola;UOC Chirurgia Vitreoretinica
-
-
Lombardy
-
Milan, Lombardy, Italien, 20142
- Rekruttering
- ASST SANTI PAOLO E CARLO - Presidio San Paolo;SC Oculistica
-
-
Piedmont
-
Novara, Piedmont, Italien, 28100
- Rekruttering
- Azienda Ospedaliero-Universitaria Ospedale Maggiore della Carità;S.C.D.U. Oftalmologia
-
Turin, Piedmont, Italien, 10126
- Rekruttering
- AOU Città della Salute e della Scienza di Torino
-
-
Sicily
-
Palermo, Sicily, Italien, 90142
- Rekruttering
- A.O.U. Policlinico Paolo Giaccone;Oculistica
-
-
-
-
-
Bielsko-Biala, Polen, 43-309
- Rekruttering
- Szpital sw. Lukasza
-
Bydgoszcz, Polen, 85-631
- Rekruttering
- OFTALMIKA Sp. z o.o
-
Bydgoszcz, Polen, 85-316
- Rekruttering
- Specjalistyczny O?rodek Okulistyczny Oculomedica
-
Gliwice, Polen, 44-100
- Rekruttering
- Niepubliczny Zak?ad Opieki Zdrowotnej PRYZMAT-OKULISTYKA
-
Krakow, Polen, 31-501
- Rekruttering
- SP ZOZ Szpital Uniwersytecki w Krakowie Oddzia? Kliniczny Okulistyki i Onkologii Okulistycznej
-
Lublin, Polen, 20-079
- Rekruttering
- Uniwersytecki Szpital Kliniczny Nr 1 w Lublinie;Klinika Chirurgii Siatkówki i Cia?a Szklistego
-
Lódz, Polen, 91-134
- Rekruttering
- Klinika Okulistyczna Jasne Błonia Sp. z o. o.
-
Olsztyn, Polen, 10-424
- Rekruttering
- Centrum Diagnostyki i Mikrochirurgii Oka LENS
-
-
Lesser Poland Voivodeship
-
Krakow, Lesser Poland Voivodeship, Polen, 31 416
- Rekruttering
- MW-med
-
-
-
-
-
Bern, Schweiz, 3007
- Rekruttering
- Berner Augenklinik
-
Olten, Schweiz, 4600
- Rekruttering
- Pallas Klinik Olten
-
Sankt Gallen, Schweiz, 9007
- Rekruttering
- Kantonsspital St. Gallen
-
-
-
-
-
Madrid, Spanien, 28046
- Rekruttering
- Hospital Universitario La Paz
-
Madrid, Spanien, 28040
- Rekruttering
- Fundacion Jimenez Diaz-UTE
-
Seville, Spanien, 41013
- Rekruttering
- Hospital Universitario Virgen del Rocio
-
Valencia, Spanien, 46015
- Rekruttering
- Hospital Arnau de Vilanova (Valencia)
-
-
-
-
-
Daegu, Sydkorea, 41944
- Rekruttering
- Kyungpook National University Hospital
-
Gyeonggi-do, Sydkorea, 16499
- Rekruttering
- Ajou University Medical Center
-
Seoul, Sydkorea, 03722
- Rekruttering
- Severance Hospital, Yonsei University Health System
-
Seoul, Sydkorea, 06591
- Rekruttering
- Seoul St Mary's Hospital
-
Seoul, Sydkorea, 07441
- Rekruttering
- Hallym University Kangnam Sacred Heart Hospital
-
Seoul, Sydkorea, 02841
- Trukket tilbage
- Korea University Anam Hospital
-
Seoul, Sydkorea, 07061
- Rekruttering
- Boramae Medical Center
-
-
-
-
-
Bangkok, Thailand, 10330
- Rekruttering
- King Chulalongkorn Memorial Hospital
-
Bangkok, Thailand, 10400
- Rekruttering
- Ramathibodi Hospital
-
Bangkok, Thailand, 10400
- Rekruttering
- Rajavithi Hospital
-
Chiang Mai, Thailand, 50200
- Rekruttering
- Maharaj Nakorn ChiangMai Hospital
-
Songkhla, Thailand, 90110
- Rekruttering
- Songklanagarind Hospital
-
-
-
-
-
Mladá Boleslav, Tjekkiet, 293 50
- Rekruttering
- Klaudianova Nemocnice - Mlada Boleslav;Ophtalmology dpt
-
Ostrava, Tjekkiet, 708 52
- Rekruttering
- Faculty Hospital Ostrava
-
Prague, Tjekkiet, 169 02
- Rekruttering
- Ustredni vojenska nemocnice
-
Prague, Tjekkiet, 100 34
- Rekruttering
- Faculty Hospital Kralovske Vinohrady
-
-
-
-
-
Chemnitz, Tyskland, 09116
- Rekruttering
- Klinikum Chemnitz gGmbH
-
Düsseldorf, Tyskland, 40225
- Rekruttering
- Universitätkslinikum Düsseldorf, Augenklinik
-
Göttingen, Tyskland, 37075
- Rekruttering
- Universitätsmedizin Göttingen Georg-August-Universität
-
Hanover, Tyskland, 30625
- Rekruttering
- Medizinische Hochschule Hannover, Klinik für Augenheilkunde
-
Rostock, Tyskland, 18057
- Rekruttering
- Universitätsmedizin Rostock
-
Würzburg, Tyskland, 97080
- Rekruttering
- Universitätsklinikum Würzburg, Augenklinik und Poliklinik
-
-
-
-
-
Innsbruck, Østrig, 6020
- Rekruttering
- Medizinische Universität Innsbruck
-
Linz, Østrig, 4021
- Rekruttering
- Kepler Universitätskliniken GmbH - Med Campus III
-
Mistelbach, Østrig, 2130
- Rekruttering
- Landesklinikum Mistelbach
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Initial diagnosis of nAMD within 24 months prior to screening
- Previous treatment with at least 3 anti-vascular endothelial growth factor (VEGF) IVT injections for nAMD per standard of care within 6 months prior to screening
- Demonstrated response to prior anti-VEGF IVT treatment since diagnosis
- Availability of historical VA data obtained at or after nAMD diagnosis and prior to the first anti-VEGF treatment for nAMD
- Availability of historical OCT image data obtained at or after nAMD diagnosis and prior to the first anti-VEGF treatment for nAMD
- BCVA of 34 letters or better using ETDRS chart at a starting distance of 4 meters at screening and enrollment visits
Exclusion Criteria:
A. Prior Ocular Treatment
Study Eye:
- History of vitrectomy surgery, submacular surgery, or other surgical intervention for age-related macular degeneration (AMD)
- Previous treatment with corticosteroid intravitreal injection
- Previous intraocular device implantation
- History of vitreous hemorrhage
- History of rhegmatogenous retinal detachment
- History of glaucoma-filtering surgery, tube shunts, or microinvasive glaucoma surgery
- History of corneal transplant
Either Eye:
- History of a severe allergic reaction or anaphylactic reaction to a biologic agent or known hypersensitivity to any component of the ranibizumab injections, study-related procedure preparations (including fluorescein), dilating drops, or any of the anesthetic and antimicrobial preparations used by a participant during the study
- Prior participation in a clinical trial involving any experimental therapies for nAMD
- Prior treatment with brolucizumab or gene therapy for nAMD
B. Macular Neovascularization/Choroidal Neovascularization (MNV/CNV) Lesion Characteristics:
Study Eye:
- Subretinal hemorrhage that involves the center of the fovea
- Subfoveal fibrosis or subfoveal atrophy
Either Eye:
- CNV due to other causes, such as ocular histoplasmosis, trauma, central serous chorioretinopathy, or pathologic myopia
- CNV masquerading lesions
C. Concurrent Ocular Conditions:
Study Eye:
- Subfoveal and/or juxtafoveal retinal pigment epithelial tear
- Any concurrent intraocular condition that would either require surgical intervention during the study to prevent or treat visual loss that might result from that condition or affect interpretation of study results
- Active intraocular inflammation
- Retinal tears or peripheral retinal breaks on depressed fundus exam that are untreated or treated within 3 months prior to the enrollment visit
- Aphakia or absence of the posterior capsule
- Uncontrolled ocular hypertension or glaucoma
- History or presence of severe posterior blepharitis, recurrent chalazia or hordeolum, severe dry eye syndrome, or severe allergic conjunctivitis
- Trichiasis
- Corneal neuropathy
- Lagophthalmos or incomplete blink
- Active or history of facial nerve palsy/paresis
Fellow (Non-study) Eye:
- Non-functioning non-study eye defined as either: BCVA of hand motion or worse OR no physical presence of non-study eye (i.e., monocular)
Either Eye:
- Any active or history of uveitis
- Active or history of keratitis, scleritis, endophthalmitis, or chronic blepharitis
- Suspected or active ocular or periocular infectious conjunctivitis or endophthalmitis
- Active or history of floppy eyelid syndrome
- Active thyroid eye disease
D. Concurrent Systemic Conditions:
- Uncontrolled blood pressure
- Active or history of autoimmune diseases
- History of stroke within the last 3 months prior to informed consent
- Atrial fibrillation diagnosed or worsened within the last 3 months prior to informed consent
- History of myocardial infarction (MI) within the last 3 months prior to informed consent
- Confirmed active systemic infection
- History of other disease, metabolic dysfunction, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of ranibizumab or placement of the implant and that might affect interpretation of the results of the study
- Use of any systemic anti-VEGF agents
- Chronic use of oral corticosteroids
- Active cancer within 12 months of enrollment except for appropriately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, and prostate cancer
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: N/A
- Interventionel model: Enkelt gruppeopgave
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: Port Delivery System (PDS)
Participants will have the PDS implant (pre-filled with 100 mg/mL of ranibizumab) [approximately 2-milligrams (mg) dose] surgically inserted in the study eye on Day 1. Participants who meet the disease activity criteria (DAC) at Week 24 or receive supplemental treatment with intravitreal (IVT) injections of ranibizumab prior to Week 24 will receive implant refill exchanges every 24 weeks (Q24W). Participants who do not meet the DAC at Week 24 and have not received supplemental treatment will receive PDS refill exchanges Q36W. |
Ranizumab will be administered via a PDS implant per the schedule described in the arm.
Andre navne:
Participants will receive ranibizumab delivered through the PDS implant. Participants will receive ranibizumab, 0.5 mg IVT injections as a supplemental treatment.
Andre navne:
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Change From Baseline in Best Corrected Visual Acuity (BCVA) Score Averaged Over Weeks 68 and 72, as Assessed Using the Early Treatment Diabetic Retinopathy Study (ETDRS) Chart at a Starting Distance of 4 Meters
Tidsramme: Baseline, Week 68, Week 72
|
BCVA letters were measured using EDTRS chart while participants were at a starting distance of 4 meter. The range of EDTRS is 0 to 100 letters. Higher scores indicate improvement in visual acuity (VA). |
Baseline, Week 68, Week 72
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Skift fra baseline i midterste punkttykkelse (CPT)
Tidsramme: Fra baseline op til uge 72
|
Fra baseline op til uge 72
|
|
|
Skift fra baseline i det centrale underfelttykkelse (CST)
Tidsramme: Fra baseline op til uge 72
|
Fra baseline op til uge 72
|
|
|
Andel af deltagere, der ikke gennemgår supplerende behandling med IVT ranibizumab før hver påfyldning-udvekslingsprocedure
Tidsramme: Op til uge 72
|
Op til uge 72
|
|
|
Antal supplerende behandlinger Deltagere modtaget i hver påfyldningscyklus
Tidsramme: Op til uge 72
|
Op til uge 72
|
|
|
Hyppigheden af undersøgelsesbesøg i hver påfyldningscyklus
Tidsramme: Op til uge 72
|
Op til uge 72
|
|
|
Antal deltagere med okulær og systemisk (ikke-okulære) bivirkning (AES)
Tidsramme: Op til cirka 19 måneder
|
Op til cirka 19 måneder
|
|
|
Antal deltagere med bivirkninger af særlige interesser (enese) og deres sværhedsgrad, herunder okulær aesis
Tidsramme: Op til cirka 19 måneder
|
Op til cirka 19 måneder
|
|
|
Antal deltagere med okulær aesis og sværhedsgrad af okulær aesis i løbet af den postoperative og opfølgningsperiode
Tidsramme: Postoperativ periode: ≤ 37 dage med indledende implantationskirurgi Opfølgningsperiode:> 37 dage efter implantationskirurgi (op til 72 uger)
|
Postoperativ periode: ≤ 37 dage med indledende implantationskirurgi Opfølgningsperiode:> 37 dage efter implantationskirurgi (op til 72 uger)
|
|
|
Antal deltagere med ugunstige enhedseffekter (ADES) og sværhedsgraden af ADES med PDS
Tidsramme: Op til cirka 19 måneder
|
Op til cirka 19 måneder
|
|
|
Antal deltagere med forventede alvorlige ugunstige enhedseffekter (ASADES) og sværhedsgraden af Asades med PDS
Tidsramme: Op til cirka 19 måneder
|
Op til cirka 19 måneder
|
|
|
Change From Baseline in BCVA Score Over Time
Tidsramme: From baseline up to Week 72
|
BCVA letters were measured using EDTRS chart while participants were at a starting distance of 4 meter. The range of EDTRS is 0 to 100 letters. Higher scores indicate improvement in VA. |
From baseline up to Week 72
|
|
Percentage of Participants Who Lose ≤ 15, ≤ 10, ≤ 5, or Gain ≥ 0 Letters in BCVA Score From Baseline Over Time
Tidsramme: From baseline up to Week 72
|
BCVA letters were measured using EDTRS chart while participants were at a starting distance of 4 meter. The range of EDTRS is 0 to 100 letters. Higher scores indicate improvement in VA. |
From baseline up to Week 72
|
|
Proportion of Participants Who Report Preferring PDS Compared With IVT Ranibizumab Treatment as Measured by the PDS Patient Preference Questionnaire (PPPQ) After First Refill (Week 24 or Week 36, Depending on Cohort) and at Week 72
Tidsramme: Weeks 24, 36 and 72
|
Weeks 24, 36 and 72
|
|
|
Proportion of Participants With Bilateral Disease Who Report Preferring PDS Compared With IVT Ranibizumab Treatment Measured by the PPPQ After First Refill (Week 24 or Week 36, Depending on Cohort) and at Week 72
Tidsramme: Weeks 24, 36 and 72
|
Weeks 24, 36 and 72
|
Samarbejdspartnere og efterforskere
Sponsor
Samarbejdspartnere
Efterforskere
- Studieleder: Clinical Trials, Hoffmann-La Roche
Publikationer og nyttige links
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Anslået)
Studieafslutning (Anslået)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- MR45625
- 2024-516924-32-00 (Ctis)
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
IPD-planbeskrivelse
For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
produkt fremstillet i og eksporteret fra U.S.A.
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .